BEMPEDOIC ACID AND EZETIMIBE
Clinical safety rating: safe
Cholestyramine decreases ezetimibe levels Fibrates may increase the risk of cholelithiasis.
Bempedoic acid inhibits ATP-citrate lyase, reducing cholesterol synthesis; ezetimibe inhibits intestinal absorption of cholesterol via Niemann-Pick C1-like 1 protein.
| Metabolism | Bempedoic acid: primarily glucuronidation (UGT2B7), minor oxidation (CYP450); ezetimibe: glucuronidation (UGT1A1, UGT1A3) to active phenolic glucuronide. |
| Excretion | Bempedoic acid is primarily excreted via the biliary/fecal route (approximately 90%), with renal excretion accounting for <10% as unchanged drug. Ezetimibe is excreted primarily in feces (78%) via biliary elimination, with renal excretion <10% as unchanged drug. |
| Half-life | Bempedoic acid: terminal half-life approximately 21 hours (range 15–24 hours), consistent with once-daily dosing. Ezetimibe: terminal half-life approximately 22 hours for ezetimibe and its glucuronide conjugate, supporting once-daily dosing. |
| Protein binding | Bempedoic acid: >99% bound to plasma proteins (primarily albumin). Ezetimibe: >90% bound to plasma proteins (albumin). The active glucuronide metabolite of ezetimibe is also highly protein bound (~90%). |
| Volume of Distribution | Bempedoic acid: Vd approximately 18 L (0.25 L/kg for a 70 kg adult), indicating moderate tissue distribution. Ezetimibe: Vd approximately 10–20 L (0.14–0.29 L/kg), suggesting distribution into tissues. |
| Bioavailability | Bempedoic acid: oral bioavailability not well characterized due to extensive presystemic metabolism; absolute bioavailability estimated at 10–20% (based on AUC ratios). Ezetimibe: rapidly absorbed and extensively glucuronidated; absolute bioavailability estimated at 35–65% due to first-pass metabolism. Both are administered orally. |
| Onset of Action | LDL-C reduction observed as early as 2 weeks after oral administration; maximal effect typically achieved by 4–8 weeks. |
| Duration of Action | LDL-C reduction persists with daily dosing; plasma concentrations remain above therapeutic threshold for full 24-hour dosing interval. No significant accumulation beyond steady state (achieved within 7–14 days). |
Bempedoic acid 180 mg and ezetimibe 10 mg orally once daily.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment (eGFR ≥30 mL/min/1.73 m²). Not recommended in severe renal impairment (eGFR <30 mL/min/1.73 m²) or ESRD. |
| Liver impairment | Contraindicated in moderate to severe hepatic impairment (Child-Pugh class B or C). No adjustment needed for mild impairment (Child-Pugh class A). |
| Pediatric use | Safety and efficacy not established in pediatric patients. |
| Geriatric use | No specific dose adjustment required; monitor renal function and potential for drug interactions due to age-related changes. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Cholestyramine decreases ezetimibe levels Fibrates may increase the risk of cholelithiasis.
| FDA category | Animal |
| Breastfeeding | Bempedoic acid: No data on excretion in human milk; molecular weight suggests possible excretion. Ezetimibe: Excreted in rat milk; unknown in humans. M/P ratio not available. Due to unknown risks, breastfeeding not recommended during therapy. Consider alternative agents. |
| Teratogenic Risk | Bempedoic acid: No human data; animal studies show no teratogenicity at exposures up to 6 times human AUC. Ezetimibe: No evidence of teratogenicity in animal studies; limited human data show no increased risk of major malformations. First trimester: No known risk, but caution advised due to lack of robust human data. Second/third trimester: No known fetal risks. Avoid use unless clearly needed. |
■ FDA Black Box Warning
No black box warning.
| Common Effects | Diarrhea |
| Serious Effects |
["Concurrent use with simvastatin >20 mg or pravastatin >40 mg","Severe hepatic impairment","Pregnancy and lactation"]
| Precautions | ["Risk of myopathy and rhabdomyolysis (especially with statins)","Hyperuricemia","Tendon rupture","Increased risk of nephrolithiasis","Elevated liver enzymes","Fetal toxicity (based on animal data)"] |
| Food/Dietary | Grapefruit juice may increase bempedoic acid exposure; avoid concurrent consumption. No specific dietary restrictions for ezetimibe; however, a low-fat, low-cholesterol diet enhances efficacy. |
Loading safety data…
| Fetal Monitoring | Monitor maternal lipid levels and liver function tests (LFTs) periodically. For ezetimibe, check LFTs if used with statins. No specific fetal monitoring required beyond routine prenatal care. Consider fetal ultrasound if used inadvertently in first trimester. |
| Fertility Effects | Bempedoic acid: No effects on fertility observed in animal studies. Ezetimibe: No adverse effects on fertility in animal studies. In humans, no data on fertility impact. Theoretical concern for hormonal alterations, but none reported. |
| Clinical Pearls | Bempedoic acid + ezetimibe is used as adjunct to diet and maximally tolerated statin for LDL-C reduction. Bempedoic acid is a prodrug activated in the liver; avoid in severe hepatic impairment. Ezetimibe inhibits intestinal cholesterol absorption. Monitor for myalgia, tendon rupture (bempedoic acid), and increased uric acid (gout risk). Check LFTs at baseline and periodically. Contraindicated with simvastatin >20 mg due to increased myopathy risk. |
| Patient Advice | Take this medication exactly as prescribed, usually once daily with or without food. · Continue a heart-healthy diet and exercise; this drug is not a substitute for lifestyle changes. · Report unexplained muscle pain, tenderness, or weakness, especially if accompanied by fever or dark urine. · Tell your doctor if you have a history of gout, as this drug can raise uric acid levels. · Avoid grapefruit juice while taking this medication (bempedoic acid interacts). · Do not take with other cholesterol-lowering medicines containing simvastatin >20 mg. |